In The News
Settlement reached with ‘highly unethical’ mastermind of Banksia class action
Full Court cites ‘wider relevance’ of copy and paste judgment
DWF snags 9 partners from Hall & Wilcox
Barristers acting on instructions from solicitor to be exempt from AML/CTF regime
ASX denies misleading investors about CHESS replacement project
Judge worries compensation for axed Qantas ground crew ‘going off into never never’
Class action in Hong Kong against Forex trader could complicate Aussie case, court told
Ex-Keystone director may claim penalty privilege in receivers’ lawsuit
Coles, Woolworths hit with class actions over discount claims
ASIC seeks $20M penalty against Kraken crypto exchange
Please login to bookmarkClose

US biotechnology firm Regeneron Pharmaceuticals has lost its opposition to a proposed patent by UK biopharmaceutical company Kymab for a method of producing an animal with part-human DNA.

Subscribe for instant access to all Lawyerly content.

Already a subscriber?
Lost your password?

Contact us to enquire about group subscriptions.
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au